drugset / Trial / NCT04921254
A Study to Assess the Safety, Tolerability and Pharmacokinetics of BSG005.
Phase 1
Unknown
72 enrolled
Biosergen AS
Greenlight Clinical · collabNucleus Network Ltd · collabSelect Pharma Pty Ltd · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase 1, double-blinded, placebo-controlled study to assess the safety, tolerability, and pharmacokinetics of BSG005 following single and multiple ascending doses in healthy subjects. The study will include a single ascending dose part and a multiple ascending dose part
Timeline
- Start
- 2021-08-23
- Primary completion
- 2023-03
- Completion
- 2023-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BSG005 | Unknown | — | Intravenous |